Malignant neoplasm of liver and intrahepatic bile ducts (C22) ICD-10-CM
The C22 code range covers malignant neoplasm of liver and intrahepatic bile ducts with 9 ICD-10-CM diagnosis codes. 8 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.
Use Additional Code
The “use additional code” indicates that a secondary code could be used to further specify the patient’s condition. This note is not mandatory and is only used if enough information is available to assign an additional code.
- code to identify:
- alcohol abuse and dependence F10
- hepatitis B B16 B18.0 B18.1
- hepatitis C B17.1 B18.2
Type 1 Excludes
A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Codes in the C22 Range 9 codes · 8 billable
- C22 Malignant neoplasm of liver and intrahepatic bile ductsNon-billable
- C22.0 Liver cell carcinoma
- C22.1 Intrahepatic bile duct carcinoma
- C22.2 Hepatoblastoma
- C22.3 Angiosarcoma of liver
- C22.4 Other sarcomas of liver
- C22.7 Other specified carcinomas of liver
- C22.8 Malignant neoplasm of liver, primary, unspecified as to type
- C22.9 Malignant neoplasm of liver, not specified as primary or secondary
Clinical Terms in This Code Range
Definitions from the National Library of Medicine for conditions coded in the C22 range.
Hep G2 Cells
A human liver tumor cell line used to study a variety of liver-specific metabolic functions.
Hepatoblastoma
A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)
About the C22 Code Range
The ICD-10 code C22 covers malignant tumors affecting the liver and intrahepatic bile ducts, including various types of liver cancers and bile duct carcinomas. These codes identify specific liver malignancies for accurate diagnosis and treatment documentation.
This section includes codes such as C22.0 for liver cell carcinoma, also known as hepatocellular carcinoma or fibrolamellar hepatocellular carcinoma, which are primary liver cancers originating from liver cells. The code C22.1 designates intrahepatic bile duct carcinoma, commonly called cholangiocarcinoma, comprising cancers arising from bile duct cells within the liver. Other codes, like C22.2 for hepatoblastoma (a liver tumor often seen in children) and C22.3 for angiosarcoma of the liver, highlight rare malignant types. Codes such as C22.7 and C22.8 capture other specified carcinomas or unspecified primary liver malignancies. Finally, C22.9 is used when the malignant liver tumor is not clearly identified as primary or secondary. Using these specific codes ensures precise classification for the ICD-10 code for liver cancer and related bile duct malignancies, assisting healthcare professionals in clinical, billing, and epidemiological tasks.
Questions About This Page
How many billable codes are in the C22 range?
Of the 9 codes in this range, 8 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.
What does the C22 range classify?
The range classifies malignant neoplasm of liver and intrahepatic bile ducts. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.
Related References
Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.
